SHE MAY NEED MORE THAN
ARTIFICIAL TEARS TO

SHE MAY NEED MORE THAN
ARTIFICIAL TEARS TO

DISRUPT
INFLAMMATION
IN DRY EYE
DISEASE1,2

DISRUPT
INFLAMMATION
IN DRY EYE
DISEASE1,2

Her eyes deserve
a change.

Her eyes deserve a change.

Not an actual patient.

Not an actual patient.

Important Safety Information

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

Improvement in signs and symptoms with Xiidra: A prescription dry eye treatment

Improvement in signs and symptoms with Xiidra: A prescription dry eye treatment

Xiidra is the only eye drop indicated to specifially treat both the signs and symptoms of dry eye disease.3-5 Xiidra improved patient-reported symptoms of eye dryness and signs of Inferior fluorescein Corneal Staining Score (ICSS) in clinical trials. Consider prescribing Xiidra for your appropriate dry eye patients.3

Clinical studies
The safety and efficacy of Xiidra were assessed in four 12-week, randomized, multicenter, double-masked, vehicle-controlled studies (N=2133). Patients were dosed twice daily. The mean age was 59 years (range, 19-97 years). The majority of patients were female (76%). Use of artificial tears was not allowed during the studies. The study end points included assessment of signs (based on ICSS on a scale of 0 to 4) and symptoms (based on patient-reported Eye Dryness Score [EDS] on a visual analogue scale of 0 to 100).3

Nearly 8 out of 10 patients treated with Xiidra did not
use artificial tears
at day 90 in the 12-month SONATA
safety study6
Participants (%) who did not report using artificial tears with Xiidra (n=220) and vehicle (n=111) since prior visit6

Vehicle=placebo.
*Based on number of participants in the safety population with data at the visit.

SONATA safety study information

The 1-year, multicenter, randomized prospective, double-masked, placebo controlled, phase 3 SONATA study evaluated the safety of Xiidra compared to vehicle in
331 adult patients who had a self-reported history of dry eye disease. The most common treatment-emergent adverse reactions (>5%) in either treatment group were instillation-site irritation, instillation-site reaction, reduced visual acuity, dry eye, and dysgeusia.6

Artificial tear use was assessed as an exploratory end point.6

After day 14 (visit 3), the use of artificial tears (≤4 times daily) was allowed as needed. The question about artificial tear use (Yes/No) was asked beginning at day 90 (visit 4). Participants with any artificial tear use during the study: vehicle=43/98 (43.9%), Xiidra=64/195 (32.8%).6

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

Click here for Full Prescribing Information.

References

  1. US Food and Drug Administration. Code of
    Federal Regulations,
    Title 21, Volume 5
    (21CFR349). Accessed April 17, 2020.

    https://www.accessdata.fda.gov/scripts/
    cdrh/cfdocs/cfcfr/
    CFRSearch.cfm?
    CFRPart=349&showFR=1

  2. Jones L, Downie LE, Korb D, et al. TFOS
    DEWS II Management and
    Therapy Report.
    Ocul Surf. 2017;15(3):575-628.

  3. Xiidra [package insert]. East Hanover, NJ:
    Novartis Pharmaceuticals Corp; June 2020.

  4. Novack GD, Asbell P, Barabino S, et al. TFOS
    DEWS II Clinical Trial Design Report. Ocul
    Surf
    . 2017;15(3):629-649.

  5. US Food and Drug Administration.
    Electronic Orange Book.
    Accessed May 1,
    2020. http://www.fda.gov/downloads/
    Drugs/
    DevelopmentApprovalProcess/
    UCM071436.pdf

  6. Donnenfeld ED, Karpecki PM, Majmudar
    PA, et al. Safety of lifitegrast
    ophthalmic
    solution 5.0% in patients with dry eye
    disease: a 1-year,
    multicenter, randomized,
    placebo-controlled study. Cornea.

    2016;35(6):741-748.